Alphatec - ATEC Stock Forecast, Price & News

6 Wall Street equities research analysts have issued "buy," "hold," and "sell" ratings for Alphatec in the last twelve months. There are currently 1 hold rating and 5 buy ratings for the stock. The consensus among Wall Street equities research analysts is that investors should "buy" ATEC shares.
View ATEC analyst ratings or view top-rated stocks.

6 analysts have issued twelve-month price objectives for Alphatec's shares. Their ATEC share price forecasts range from $9.50 to $20.00. On average, they predict the company's share price to reach $16.25 in the next year. This suggests a possible upside of 4.2% from the stock's current price.
View analysts price targets for ATEC or view top-rated stocks among Wall Street analysts.

Alphatec's stock was trading at $12.35 at the beginning of the year. Since then, ATEC stock has increased by 26.3% and is now trading at $15.60.
View the best growth stocks for 2023 here.

Alphatec saw a increase in short interest in the month of March. As of March 15th, there was short interest totaling 6,700,000 shares, an increase of 9.3% from the February 28th total of 6,130,000 shares. Based on an average daily volume of 982,400 shares, the days-to-cover ratio is presently 6.8 days. Currently, 10.6% of the company's stock are short sold.
View Alphatec's Short Interest.

The company is scheduled to release its next quarterly earnings announcement on Thursday, May 4th 2023.
View our ATEC earnings forecast.

Alphatec Holdings, Inc. (NASDAQ:ATEC) released its earnings results on Thursday, November, 4th. The medical technology company reported ($0.43) EPS for the quarter, missing the consensus estimate of ($0.23) by $0.20. The medical technology company earned $62.88 million during the quarter, compared to analyst estimates of $61.43 million. Alphatec had a negative net margin of 43.36% and a negative trailing twelve-month return on equity of 575.45%. During the same quarter in the prior year, the firm earned ($0.18) EPS.

ETFs with the largest weight of Alphatec (NASDAQ:ATEC) stock in their portfolio include Jacob Forward ETF (JFWD), SPDR S&P Health Care Equipment ETF (XHE), Invesco Nasdaq Future Gen 200 ETF (QQQS), First Trust Nasdaq Lux Digital Health Solutions ETF (EKG), Principal Healthcare Innovators ETF (BTEC), Global X Aging Population ETF (AGNG).iShares Micro-Cap ETF (IWC) and

Alphatec updated its FY 2023 earnings guidance on Tuesday, February, 28th. The company provided EPS guidance of for the period. The company issued revenue guidance of $438.00 million-$438.00 million, compared to the consensus revenue estimate of $426.30 million.

19 employees have rated Alphatec Chief Executive Officer Pat Miles on Glassdoor.com. Pat Miles has an approval rating of 72% among the company's employees. 63.0% of employees surveyed would recommend working at Alphatec to a friend.

Based on aggregate information from My MarketBeat watchlists, some companies that other Alphatec investors own include Macrocure Ltd. - Ordinary Share (MCUR), LinnCo (LNCOQ), California Resources (CRC), Sorrento Therapeutics (SRNE), Catalyst Pharmaceuticals (CPRX), (GBSN) (GBSN), Idera Pharmaceuticals (IDRA), Athersys (ATHX), Anavex Life Sciences (AVXL) and BioCryst Pharmaceuticals (BCRX).

Alphatec trades on the NASDAQ under the ticker symbol "ATEC."

Shares of ATEC stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

One share of ATEC stock can currently be purchased for approximately $15.60.

Alphatec (NASDAQ:ATEC) has a market capitalization of $1.73 billion and generates $350.87 million in revenue each year. The medical technology company earns $-152,150,000.00 in net income (profit) each year or ($1.47) on an earnings per share basis.

The company employs 561 workers across the globe.

Alphatec's mailing address is 5818 EL CAMINO REAL, CARLSBAD CA, 92008. The official website for the company is www.atecspine.com. The medical technology company can be reached via phone at (760) 431-9286, via email at ir@alphatecspine.com, or via fax at 800-922-1356.